A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors (NCT05538130)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called "BRAF V600" * received required prior treatment for cancer per cohort assigned. All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day. Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.
Who can join: Review the eligibility criteria below.
Location: The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (83 Sites)
- The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
- The University of Alabama at Birmingham — Birmingham, Alabama
- University of Alabama at Birmingham - Phase I Clinical Trials Unit — Birmingham, Alabama
- Highlands Oncology Group, PA — Fayetteville, Arkansas
- Highlands Oncology Group, PA — Rogers, Arkansas
- Highlands Oncology Group, PA — Springdale, Arkansas
- The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate — Los Angeles, California
- Keck Hospital of USC — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Keck Medical Center of USC Pasadena — Pasadena, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
- UCSF Medical Center, Investigational Pharmacy — San Francisco, California
- The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only) — Santa Monica, California
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
- Moffitt McKinley Hospital — Tampa, Florida
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Massachusetts General Hospital — Boston, Massachusetts
- Ophthalmic Consultants of Boston Inc (OCB) — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Mass General Waltham — Waltham, Massachusetts
- Brigitte Harris Cancer Pavilion — Detroit, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.